Impact of Antiplatelet Therapy in Heart DiseaseRenda G. · de Caterina R.
Institute of Cardiology and Center of Excellence on Aging, ‘G. d’Annunzio’ University, Chieti, Italy
Because platelet activation plays an important pathophysiological role in acute coronary syndromes, antiplatelet agents are a mainstay of cardiovascular therapy, both in high-risk primary prevention and in secondary prevention. This is usually done with aspirin in all such cases, and adding a P2Y12 inhibitor in secondary prevention usually for 1 year after an acute coronary syndrome, especially after stent implantation. P2Y12 inhibitors include ticlopidine (now rarely used), clopidogrel, prasugrel, and ticagrelor. In the setting of high-risk acute coronary syndromes treated with percutaneous coronary interventions, the addition of a glycoprotein IIb/IIIa antagonist, especially abciximab, is contemplated. Conversely, the role of antiplatelet therapy in preventing stroke after atrial fibrillation has been recently downgraded in most risk classes, in favor of anticoagulants. This chapter provides a general overview of the use of antiplatelet agents in heart disease.
|Direct payment||This item at the regular price: USD 33.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00